| Synonyms: | |
| Status: | Phase 3 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | NYU6UTW25B |
| InChI Key | KPYSYYIEGFHWSV-QMMMGPOBSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C10H12ClNO2 |
| Molecular Weight | 213.66 |
| AlogP | 1.86 |
| Hydrogen Bond Acceptor | 2.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 4.0 |
| Polar Surface Area | 63.32 |
| Molecular species | ZWITTERION |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 14.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| AGONIST | GABA-B receptor agonist | PubMed |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Ion channel
Voltage-gated ion channel
Voltage-gated sodium channel
|
- | - | - | - | 12 | |
|
Membrane receptor
Family C G protein-coupled receptor
Small molecule receptor (family C GPCR)
Neurotransmitter receptor (family C GPCR)
GABA-B receptor
|
1000 | 32-140 | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Fragile X Syndrome | 3 | D005600 | ClinicalTrials |
| Child Development Disorders, Pervasive | 3 | D002659 | ClinicalTrials |
| Muscle Spasticity | 3 | D009128 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 69308-37-8 |
| ChEMBL | CHEMBL301742 |
| DrugBank | DB08891 |
| EPA CompTox | DTXSID90219366 |
| FDA SRS | NYU6UTW25B |
| Guide to Pharmacology | 3428 |
| PDB | 2C0 |
| PubChem | 44602 |
| SureChEMBL | SCHEMBL351220 |
| ZINC | ZINC000000000061 |